AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events

For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of Medici